You are here: Industry Insights > Diabetes

News List

Predicting the risk of heart disease, diabetes and more using millions of gene variants fiercebiotech
August 14, 2018
If physicians could predict which of their patients are more likely to develop serious diseases like breast cancer, type 2 diabetes and coronary artery disease, they could offer personalized preventive care that’s only minimally available today.
Sanofi diabetes executive makes the jump to Omeros to become CMO fiercebiotech
August 03, 2018
In keeping with the recent trend of top R&D executives moving to smaller biotechs, Sanofi’s Eckhard Leifke, M.D., the giant’s global head of diabetes late-stage development......
MannKind signs distribution deal with Tanner for diabetes drug pharmaceutical-technology
August 01, 2018
US-based therapeutic products developer MannKind has signed an agreement with Tanner Pharma Group for the distribution of its Afrezza Inhalation Powder in countries outside the US.
Pfizer drops diabetes and cancer drugs from clinical pipeline fiercebiotech
August 01, 2018
Pfizer has culled Type 1 diabetes and cancer drugs from its early-phase pipeline (PDF). The actions affect anti-IL7R antibody PF-06342674 and third-generation, mutant-selective EGFR tyrosine kinase inhibitor PF-06747775.
Lilly and Sigilon partner to develop diabetes type I therapies pharmatimes
July 18, 2018
Eli Lilly and Sigilon Therapeutics have announced a global collaboration to develop encapsulated cell therapies for type I diabetes.
Diabetes Diagnosis 'Silver Lining'? Other Family Members' Health May Improve drugs
July 10, 2018
A new study found that partners of people newly diagnosed with diabetes were 50 percent more likely to attend weight management classes and 25 percent more likely to get medication to help quit smoking.
Novo’s oral semaglutide bests MSD’s Januvia on HbA1c reduction pharmatimes
July 05, 2018
Novo Nordisk has presented data from a Phase IIIa study showing that an oral formulation of its GLP-1 analogue semaglutide was better at reducing blood sugar than MSD’s DPP-4 inhibitor Januvia in patients with type II diabetes.
Novo Nordisk trumpets more Januvia-topping data for oral semaglutide fiercepharma
July 02, 2018
Just eight days after posting a trial win over Merck diabetes stalwart Januvia, Novo Nordisk candidate semaglutide is back with another.
J&J agrees to sell LifeScan unit for $2.1B biospectrumasia
June 14, 2018
Johnson & Johnson accepted Platinum Equity's $2.1 billion offer for LifeScan, the company's blood glucose monitoring unit known for its OneTouch brand of glucose meters and insulin pumps.
Hydrogel could enable pancreatic islet transplants for diabetes fiercebiotech
June 11, 2018
Scientists searching for Type 1 diabetes cures have long been interested in transplanting functioning pancreatic islet cells into patients, but the danger of immune system rejection has been an obstacle.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 37 38 Next page